Breadcrumb Home Amgen Politics & Policy PBM bills drove lobbying spending in 2023 Payment Cigna paying members to use biosimilars draws providers ire Finance Week Ahead: Bevy of healthcare companies prepare to release quarterly results Legal Manufacturers sue Trump administration over price disclosure Finance Week Ahead: Aetna, Anthem expected to continue positive earnings news Sponsored Content Provided By Amgen and Novartis The Burden of Migraine Technology Pfizer's biosimilar for chemo patients OK'd to vie against Amgen's Neupogen Opinion Editorial: Tax reform is going nowhere Government Justices hear dispute over lower-cost biotech drugs sales Government FDA approves lower-cost alternative to biotech drug Humira Load More Sponsored Content
